Archives
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
BRCA2 Shields RAD51 Filaments from PARP Inhibitor Disruption
2026-06-03
This study elucidates a previously uncharacterized protective role of BRCA2 in maintaining RAD51 filament stability by preventing PARP1 retention during PARP inhibitor (PARPi) therapy. These findings clarify the molecular basis of selective cytotoxicity in BRCA2-deficient, homologous recombination-deficient cancers and have practical implications for the design of targeted DNA repair deficiency treatments.
-
Clasto-Lactacystin β-lactone: Precision Tools for Decoding V
2026-06-03
Explore how Clasto-Lactacystin β-lactone, a potent proteasome inhibitor, empowers next-generation research at the intersection of viral immunity and regulated cell death. This article delivers a unique, evolutionary perspective on ubiquitin-proteasome pathway manipulation for advanced assay design.
-
Ganetespib (STA-9090): Redefining Hsp90 Inhibition in Cancer
2026-06-02
Explore how Ganetespib (STA-9090), a potent Hsp90 inhibitor, is advancing cancer research through unique chaperone disruption mechanisms and implications for innovative assay design. This article provides new insights beyond standard workflows, contrasting prior scenario-based and translational oncology perspectives.
-
Morin: Multifunctional Flavonoid for Neuroprotective Researc
2026-06-02
Explore how Morin, a natural flavonoid, advances neuroprotective and cardioprotective research through unique mechanisms such as AMPD inhibition and fluorescent ion chelation. Discover new assay strategies and practical insights not covered in standard reviews.
-
In Vitro Efficacy of Midecamycin as an Acetoxy-Substituted M
2026-06-01
The reference study systematically evaluated midecamycin, an acetoxy-substituted macrolide antibiotic, for its in vitro activity against a broad spectrum of Gram-positive and Gram-negative bacteria. The findings clarify midecamycin's selective efficacy and resistance profile, providing critical data for researchers designing antibacterial assays and resistance studies.
-
Efficient Synthesis of Deuterium-Labeled Degarelix Acetate
2026-06-01
This study introduces a practical, high-yield method for synthesizing deuterium-labeled degarelix acetate, a third-generation GnRH receptor antagonist vital for clinical pharmacokinetic studies. The workflow leverages D2O/D3PO4 as a deuterium source and provides robust characterization, facilitating future absorption, distribution, metabolism, and excretion (ADME) research in androgen-related diseases.
-
Addressing Pollen Interference in EEM Fluorescence for Bioae
2026-05-31
The reference study presents a robust machine learning approach to remove pollen spectral interference in excitation–emission matrix (EEM) fluorescence spectroscopy, significantly improving the classification accuracy of hazardous bioaerosols. This advancement enhances the reliability of rapid detection methods for public health protection.
-
Defining Proteoform-Specific Drug Interactions in Native Mem
2026-05-30
This article reviews a landmark study that uses native mass spectrometry to directly characterize proteoform-specific interactions between drugs and membrane proteins in their physiological lipid environment. The findings clarify how post-translational modifications and alternative splicing shape off-target effects, enhancing the precision of drug targeting strategies, particularly for cGMP-specific phosphodiesterase type 5 inhibitors.
-
PARP1-Driven Oxaliplatin Resistance and Sensitization in Gas
2026-05-29
This study reveals that PARP1 overexpression is a critical driver of oxaliplatin resistance in gastric cancer. It demonstrates that oxaliplatin's inhibition of CDK1 can sensitize BRCA-proficient tumors to PARP inhibition, suggesting a new combinatorial therapeutic strategy.
-
Molecular Mechanisms of TRPM3 Regulation by Neurosteroids an
2026-05-29
This study reveals the structural basis for neurosteroid and anticonvulsant modulation of TRPM3, a key ion channel implicated in pain and neurodevelopmental disorders. High-resolution cryo-EM structures provide insights into ligand binding and gating, informing drug development and functional assays.
-
VX-702: Unveiling Dual-Action p38α MAPK Inhibition Dynamics
2026-05-28
Explore the mechanistic depth of VX-702, a potent p38α MAPK inhibitor, and discover how recent structural insights redefine selectivity and assay optimization for inflammation and cardiovascular research.
-
Pifithrin-α (PFTα): Enabling Precision p53 Inhibition in Fer
2026-05-28
Discover how Pifithrin-α, a robust p53 inhibitor, empowers researchers to dissect p53-dependent apoptosis and ferroptosis in neurotoxicity models. This article uniquely explores evidence-based protocol design, mechanistic depth, and translational insights beyond standard workflow guides.
-
HO-1 Modulation by Isochlorogenic Acid A Disrupts HBV Replic
2026-05-27
The referenced study uncovers how isochlorogenic acid A impairs hepatitis B virus replication through upregulation of heme oxygenase-1 (HO-1) and subsequent modulation of intracellular reactive oxygen species (ROS). These findings clarify key molecular steps in the antiviral action of natural compounds and highlight the potential of HO-1 as a therapeutic target in viral and metabolic disease research.
-
Leveraging L1023 Anti-Cancer Compound Library for STING Path
2026-05-27
Explore how the L1023 Anti-Cancer Compound Library empowers advanced cancer research by enabling high-throughput screening of pathway-targeted agents, including BRAF kinase inhibitors, and learn how new STING pathway insights drive assay innovation.
-
DNA Damage Pathways Modulate Calicheamicin ADC Sensitivity i
2026-05-26
This study uses genome-wide CRISPR screening to identify DNA damage sensing and TP53 pathway genes as key modulators of sensitivity to calicheamicin-based antibody–drug conjugates (ADCs) in acute leukemia. The findings delineate actionable targets for combination therapies and highlight the specificity of DNA repair pathway involvement in drug response.